ELAN - Elanco Animal Health Inc Stock Price, Fair Value and News

12.90USD+0.08 (+0.62%)Market Closed

Market Summary

USD12.90+0.08

Market Closed

0.62%

ELAN Stock Price

View Fullscreen

ELAN RSI Chart

ELAN Valuation

Market Cap

6.3B

Price/Earnings (Trailing)

-4.87

Price/Sales (Trailing)

1.45

EV/EBITDA

-36.05

Price/Free Cashflow

23.23

ELAN Price/Sales (Trailing)

ELAN Profitability

EBT Margin

-29.58%

Return on Equity

-21.5%

Return on Assets

-9.29%

Free Cashflow Yield

4.3%

ELAN Fundamentals

ELAN Revenue

Revenue (TTM)

4.4B

Rev. Growth (Yr)

-4.14%

Rev. Growth (Qtr)

16.43%

ELAN Earnings

Earnings (TTM)

-1.3B

Earnings Growth (Yr)

-68.93%

Earnings Growth (Qtr)

122.7%

Breaking Down ELAN Revenue

Last 7 days

-0.4%

Last 30 days

-28.2%

Last 90 days

-3.3%

Trailing 12 Months

5.3%

How does ELAN drawdown profile look like?

ELAN Financial Health

Current Ratio

3.29

Debt/Equity

0.95

Debt/Cashflow

0.07

ELAN Investor Care

Shares Dilution (1Y)

0.33%

Diluted EPS (TTM)

-2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.4B	0	0	0
2023	4.4B	4.3B	4.4B	4.4B
2022	4.7B	4.6B	4.5B	4.4B
2021	3.9B	4.6B	4.8B	4.8B
2020	3.0B	2.8B	2.9B	3.3B
2019	3.1B	3.1B	3.1B	3.1B
2018	2.9B	3.0B	3.0B	3.1B
2017	2.9B	2.9B	2.9B	2.9B
2016	0	0	0	2.9B
2015	0	0	0	2.9B

Get all data in R, Python etc through our Historical Stock Data APIs

About Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.

CEO	Mr. Jeffrey N. Simmons
WEBSITE	elanco.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	9000

Elanco Animal Health Inc Frequently Asked Questions

What is the ticker symbol for Elanco Animal Health Inc? What does ELAN stand for in stocks?

ELAN is the stock ticker symbol of Elanco Animal Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Elanco Animal Health Inc (ELAN)?

As of Thu Jul 25 2024, market cap of Elanco Animal Health Inc is 6.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELAN stock?

You can check ELAN's fair value in chart for subscribers.

Is Elanco Animal Health Inc a good stock to buy?

The fair value guage provides a quick view whether ELAN is over valued or under valued. Whether Elanco Animal Health Inc is cheap or expensive depends on the assumptions which impact Elanco Animal Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELAN.

What is Elanco Animal Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ELAN's PE ratio (Price to Earnings) is -4.87 and Price to Sales (PS) ratio is 1.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELAN PE ratio will change depending on the future growth rate expectations of investors.